Previous close | 10.25 |
Open | 10.50 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 35.00 |
Expiry date | 2026-01-16 |
Day's range | 9.55 - 10.50 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
PRINCETON, N.J., June 04, 2024--Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or....